RSS Feed en-us Copyright (c) 2021 Inc. All rights reserved. 4/21/2021 5:23:54 PM <![CDATA[Marimaca Copper "OUTPERFORM"]]>Wed, 21 Apr 2021 11:59:00 EST<![CDATA[Oil Falls on Increased COVID cases ]]>Wed, 21 Apr 2021 10:35:00 EST, April 21, 2021

Oil Falls on Increased COVID cases

Oil prices fell for a second day on Wednesday on concerns that soaring COVID-19 cases in India will drive down fuel demand in the world’s third biggest oil importer.

Brent crude futures for June fell 78 cents, or 1.1%, to $65.79 U.S. per barrel, after dropping 48 cents on Tuesday.

U.S. West Texas Intermediate crude futures for June fell 77 cents, or 1.3%, to $61.86 a barrel. The May contract expired on Tuesday down 1.5% at $62.44.

India, also the world’s third-largest oil user, on Tuesday reported its worst daily death toll from the virus and is facing an oxygen supply crisis to treat patients. Large parts of the country are now under lockdown due to a huge second wave of the pandemic.

Further weighing on the market, data from the American Petroleum Institute industry group showed U.S. crude oil and distillate stocks rose in the week ended April 16, according to two market sources, compared with analysts’ forecasts for declines in crude and distillate inventories.

Crude stocks rose by 436,000 barrels, API reported, according to the sources. Analysts polled by Reuters had expected a three-million-bbl drawdown in crude stocks.

Distillate stocks, which include diesel, heating oil and jet fuel, rose by 655,000 barrels, compared with analysts’ forecasts for a one-million-barrel decline.

The U.S. Energy Information Administration will release its inventory data for last week later on Wednesday.

<![CDATA[Amazon Introduces Palm-Scanning Payment Method At Whole Foods ]]>Wed, 21 Apr 2021 07:18:00 EST, April 21, 2021

Amazon Introduces Palm-Scanning Payment Method At Whole Foods

Amazon (NASDAQ:AMZN) is introducing a palm-scanning payment system at select Whole Foods locations.

The online retail giant said palm scanning will initially rollout at Whole Foods stores in Seattle, Washington before expanding to other locations.

"Amazon One," which debuted in September 2020 and is currently in use at about a dozen Amazon physical stores, allows shoppers to pay for items by placing their palm over a scanning device. The first time that shoppers use the kiosk, they have to insert a credit card to link it with their palm print. But after that, shoppers can pay simply by holding their hand over the kiosk.

Amazon One is distinct from the company’s "Just Walk Out" technology, which allows shoppers to pick up items and walk out of the store without going through a checkout. However, the two technologies can work together, and Amazon employs them both at its cashier-less "Amazon Go" stores.

The palm-scanning technology will be offered as just one of many payment options at participating Whole Foods stores, Amazon said, and won’t impact store employees’ job responsibilities. Amazon acquired grocery chain Whole Foods in 2017 for more than $13 billion U.S.

Amazon has said it hopes to sell the palm-scanning technology to other retailers, stadiums and office buildings. Last September, Amazon said it was in "active discussions with several potential customers."

As Amazon has expanded and validated palm-scanning technology as a form of payment, privacy and security experts have raised concerns about the dangers of shoppers’ handing over biometric data to big companies.

<![CDATA[Economic Calendar]]>Wed, 21 Apr 2021 05:23:54 EST 2021


Thursday, April 1, 2021 Markit Canada Manufacturing PMI: 9:30 am Mar The headline seasonally adjusted IHS Markit Canada Manufacturing Purchasing Managers’ Index® (PMI®) registered 58.5 in March, up considerably from 54.8 in February, to become the highest reading in over 10 years of data collection. The headline seasonally-adjusted IHS Markit Canada Manufacturing Purchasing Managers’ Index registered 54.4 in January, down sharply from 57.9 in December.
Thursday, April 1, 2021 Building Permits: 8:30am Feb The total value of building permits issued in February broke the $10 billion mark for the first time, as a jump in the non-residential sector more than offset the decline in the residential sector. Permits rose rising 8.2% to $9.9 billion and surpassing the previous record of $9.6 billion set in April 2019. These gains were driven primarily by the residential sector.
Wednesday, April 7, 2021 IVEY Purchasing Managers Index: 10:00am Mar The index catapulted to 72.9 in March, towering above the 60.0 reading in February, and racing away from the 26.0 figure for March 2020 The index registered 60 in February, towering above the 48.4 reading in January, and also surpassing the 54.1 figure for February 2020
Wednesday, April 7, 2021 Canadian International Merchandise Trade: 8:30am Feb Canada's merchandise exports decreased by 2.7% in February, while imports fell 2.4%. As a result, Canada's merchandise trade surplus with the world narrowed from $1.2 billion in January to $1.0 billion in February. Canada posted a trade surplus of $1.4 billion in January, the first since May 2019, owing to a sharp 8.1% increase in merchandise exports. Imports rose 0.9% in January compared with the previous month.
Friday, April 9, 2021 Labour Force Survey: 8:30am Mar Employment rose 303,000 (or 1.6%) in March. Combined with an increase of 259,000 (1.4%) in February, this brought employment to within 1.5% (-296,000) of its February 2020 level. The unemployment rate fell 0.7 percentage points to 7.5%, the lowest level since February 2020. The economy created 259,000 jobs in February, after falling by 266,000 over the previous two months, bringing the jobless rate to 8.2%.
Thursday, April 15, 2021 Monthly Survey of Manufacturing: 8:30am Feb Manufacturing sales decreased 1.6% to $55.4 billion in February, following a 3.4% increase in January. Lower sales of motor vehicles and motor vehicle parts were largely responsible for the decline. Manufacturing sales rose 3.1% to $56.2 billion in January, exceeding the level observed before the COVID-19 pandemic (February 2020) for the first time.
Thursday, April 15, 2021 CREAstats - MLS Sales: 8:30am Mar Home sales recorded over Canadian MLS® Systems climbed 5.2% between February and March 2021 to set another new all-time record. Home sales recorded over Canadian MLS® Systems climbed 6.6% between January and February to set another new all-time record.
Friday, April 16, 2021 Canada's International Transactions in Securities: 8:30am Feb Canadian investors acquired $10.5 billion of foreign securities in February, continuing a trend of net purchases that began in May 2020. Meanwhile, foreign investment in Canadian securities reached $8.5 billion, led by strong acquisitions of Canadian shares. Foreign investment in Canadian securities totaled $1.3 billion in January, the lowest investment in six months. Meanwhile, Canadian investors acquired $3.5 billion in foreign securities, down considerably from a $26.9 billion investment in December.
Friday, April 16, 2021 Wholesale Trade: 8:30am Feb Sales of wholesale products fell 0.7% in February to $68.8 billion, the second decline in three months. Despite the drop, sales in February were the second highest on record for the sector. Sales of wholesale products rose 4.0% in January to $69.2 billion, the eighth increase in the past nine months.
Monday, April 19, 2021 Housing Starts: 8:15am Mar The trend in housing starts was 273,664 units in March 2021, up from 252,636 units in February 2021, according to Canada Mortgage and Housing Corporation (CMHC). The trend in housing starts was 242,777 units in February, down from 244,963 units in January
Wednesday, April 21, 2021 BoC Interest Rate Decision: 10:00am Apr The Bank of Canada today held its target for the overnight rate at the effective lower bound of 0.25%, with the Bank Rate at 0.5%and the deposit rate at 0.25% The Bank of Canada today held its target for the overnight rate at the effective lower bound of 0.25%, with the Bank Rate at 0.5% and the deposit rate at 0.25%
Wednesday, April 21, 2021 Consumer Price Index: 8:30am Mar CPI rose 2.2% on a year-over-year basis in March, up from a 1.1% gain in February. On a seasonally adjusted monthly basis, the CPI rose 0.1% in March. CPI rose 1.1% on a year-over-year basis in February, up from a 1.0% increase in January. On a seasonally-adjusted monthly basis, the CPI rose 0.1% in February.
Thursday, April 22, 2021 New Housing Price Index: 8:30am Mar --- New home prices in February rose at their fastest pace since February 1989. New house prices were up in 22 of the 27 census metropolitan areas surveyed, pushing the national index up 1.9% in February.
Wednesday, April 28, 2021 Retail Trade: 8:30am Feb --- Retail sales fell for the second consecutive month, down 1.1% to $52.5 billion in January.
Thursday, April 29, 2021 Payroll Employment, Earnings and Hours: 8:30am Feb --- The total number of payroll employees in January was 1.2 million (or 7%) lower than in February 2020.
Friday, April 30, 2021 Industrial Product Price Index: 8:30am Mar --- In February, the Industrial Product Price Index rose 2.6%, the largest monthly increase in the index in over 40 years, since January 1980's advance of 3.8%.
Friday, April 30, 2021 Raw Materials Price Index: 8:30am Mar --- The Raw Materials Price Index was up 6.6% month over month, the biggest gain since May 2020's hike of 15.0%.
Friday, April 30, 2021 GDP: 8:30am Feb --- Real gross domestic product edged up 0.1% in December as 12 of 20 industrial sectors were up in the month.
<![CDATA[Bank Rate Stays Still, but Economic Outlook Brighter ]]>Wed, 21 Apr 2021 10:28:00 EST Rate Stays Still, but Economic Outlook Brighter

Things are staying put on the borrowing front, but with a bit of an upward twist this time.

The Bank of Canada is keeping its key interest rate target on hold as it raises its outlook for economic growth this year.

The central bank says its key rate remains at 0.25% where it has held steady for more than a year.

The decision came as the Bank of Canada raised its prediction for economic growth this year to 6.5%, up from an earlier forecast of 4%.

Economic growth is expected to moderate after that, according to the central bank's quarterly outlook report.

The improving conditions are why the bank also says today it will ease off federal government bond purchases which are part of its quantitative-easing program designed to aid the economy.

The Bank of Canada says it plans to keep its up its efforts to aid the economy until slack is absorbed and inflation is back at its 2% target, which the bank now sees happening later next year.

<![CDATA[Pandemic Concerns Weigh, Asia Mostly Falls]]>Wed, 21 Apr 2021 06:33:00 EST, April 21, 2021

Pandemic Concerns Weigh, Asia Mostly Falls

Stocks in Asia-Pacific largely fell on Wednesday as a surge in coronavirus cases in countries like India weighed on the economic outlook and investor sentiment.

The Nikkei 225 retreated another 591.83 points, or 2%, to 28,505.55.

The Japanese yen traded at 108.04 per U.S. dollar, still stronger than levels above 109.2 against the greenback seen last week.

In Hong Kong, the Hang Seng index tanked 513.81 points, or 1.8%, to 28,621.92.

In Hong Kong, shares of China Eastern Airlines fell 1.9% and Cathay Pacific slipped 2.1% in afternoon trade. Singapore Airlines’ stock also shed 1.6%.

Australia’s retail sales rose 1.4% in March from February, according to preliminary data released Wednesday by the country’s Bureau of Statistics. That was higher than expectations in a Reuters poll for a 1% gain.

Reopening plays like airlines mostly fell, with shares of Qantas Airways in Australia dropping 1.4% while ANA Holdings in Japan declined 0.41%. Japan Airlines, however, gained 0.66%.

The Australian dollar changed hands at $0.7718, lower than levels above $0.777 seen yesterday.

In other markets

In Shanghai, the CSI 300 regained 15.38 points, or 0.3%, to 5,098.75

In Singapore, the Straits Times index subtracted 37.11 points, or 1.2%, to 3,155.08.

In Korea, the Kospi index backtracked 49.04 points, or 1.5%, to 3,171.66.

In Taiwan, the Taiex index slouched 121.76 points, or 0.7%, to 17,202.11

In New Zealand, the NZX 50 ditched 143.21 points, or 1.1%, to 12,535.34.

In Australia, the ASX 200 retreated 20.28 points, or 0.3%, to 6,997.48.

<![CDATA[Number Of SPAC Deals Plummets In April ]]>Wed, 21 Apr 2021 08:13:00 EST interest in special purpose acquisition company (SPAC) deals appears to be cooling off.

After more than 100 new SPAC deals in March, issuance is nearly at a standstill with just 10 SPACs undertaken so far in April, according to data from SPAC Research.

The slowdown comes after the U.S. Securities and Exchange Commission (SEC) has started scrutinizing SPAC deals and the financials of the companies involved in the reverse mergers. More than 90% of SPACs have been audited by just two accounting firms over the past six years, according to SPAC Research.

Many SPAC stocks are falling because of the increased regulator scrutiny. Collectively, SPAC stocks are down 20% year-to-date after making their market debut, according to SPAC Research.

Signs have also emerged that retail investors might be having second thoughts about SPACs. Bank of America’s (NYSE:BAC) client flows showed that retail SPAC buying slowed significantly in April.

<![CDATA[TSXV New Listings]]>Fri, 17 Jan 2020 06:20:00 EST Company Name Ticker Date ANC Capital Ventures Inc. ANCV.P 17-01-2020 Vincero Capital Corp VCO.P 07-02-2020 Good2Go2 Corp. GOAL.P 13-02-2020 Eclipse Gold Mining Corporation EGLD 18-02-2020 Spectre Capital Corp. SOO.P 21-02-2020 Aphelion Capital Corp. APHE.P 26-02-2020 Canada Nickel Company Inc. CNC 27-02-2020 E36 Capital Corp. ETSC.P 28-02-2020 Zenith Capital Corporation ZENI.P 06-03-2020 Baltic I Acquisition Corp. BLTC.P 11-03-2020 Hansco Capital Corp. HCO.P 12-03-2020 Hakken Capital Corp. HAKK.P 13-03-2020 Moon River Capital Ltd. MOO.P 20-03-2020 Fosterville South Exploration Ltd. FSX 14-04-2020 Newtopia Inc. NEWU 04-05-2020 Standard Uranium Ltd. STND 04-05-2020 Trillium Acquisition Corp. TCK.P 05-05-2020 Israel Capital Canada Corp. IL.P 08-05-2020 Spectra7 Microsystems Inc. SEV 22-05-2020 Whatcom Capital Corp. WHAT.P 02-06-2020 CloudMD Software & Services Inc. DOC 04-06-2020 Freeform Capital Partners Inc. FRM.P 17-06-2020 Kalon Acquisition Corp. KAC.P 26-06-2020 Blue Rhino Capital Corp. RHNO.P 13-07-2020 Lamaska Capital Corp. LCC.P 13-07-2020 Solaris Resources Inc. SLS 13-07-2020 RIWI Corp. RIWI 27-07-2020 New Found Gold Corp. NFG 11-08-2020 GHP Noetic Science-Psychedelic Pharma Inc. PSYF.P 11-08-2020 Ridgeline Minerals Corp. RDG 13-08-2020 Valencia Capital Inc. VAL.P 14-08-2020 Sun Peak Metals Corp. PEAK 17-08-2020 Capitan Mining Inc. CAPT 21-08-2020 Spartan Acquisition Corp. VDKA.P 31-08-2020 Reitmans (Canada) Limited RET 03-09-2020 Altina Capital Corp. ALTN.P 21-09-2020 Deveron Corp. FARM 21-09-2020 Altina Capital Corp. ALTN.P 21-09-2020 Marwest Apartment Real Estate Investment Trust MAR.P 22-09-2020 Rubicon Organics Inc. ROMJ 22-09-2020 Exro Technologies Inc. EXRO 22-09-2020 Stormcrow Holdings Corp. CROW.P 23-09-2020 Nova Royalty Corp. NOVR 01-10-2020 Carebook Technologies Inc. CRBK 06-10-2020 Justify Capital Corp. JST.P 15-10-2020 Montage Gold Corp. MAU 23-10-2020 VLCTY Capital Inc. VLCY.P 28-10-2020 kadestone Capital Corp. KDSX 29-10-2020 Pivotree Inc. PVT 30-10-2020 Hapbee Technologies, Inc. HAPB 30-10-2020 High Mountain 2 Capital Corporation HMCC.P 05-11-2020 High Tide Inc. HITI 19-11-2020 AIM5 Ventures Inc. AIME.P 24-11-2020 Whitehorse Gold Corp. WHG 25-11-2020 Element 29 Resources Inc. ECU 03-12-2020 Tempus Resources Ltd. TMRR 07-12-2020 Cuspis Capital II Ltd. CCII.P 11-12-2020 Jabbo Capital Corp. JAB.P 14-12-2020 Cross Border Capital I Inc. CBX.P 22-12-2020 EFH Holdings Inc. EFH 23-12-2020 Empress Royalty Corp. EMPR 29-12-2020 E2Gold Inc. ETU 30-12-2020 Skylight Health Group Inc. SHG 06-01-2021 HAW Capital 2 Corp. HAW.P 08-01-2021 Summa Silver Corp. SSVR 11-01-2021 Compass Venture Inc. CVI.P 21-01-2021 Railtown Capital Corp RLT.P 28-01-2021 Inc. TOI 01-02-2021 Leviathan Gold Ltd. LVX 10-02-2021 Aumento Capital VIII Corp. AMU.P 17-02-2021 Jesmond Capital Ltd. JES.P 18-02-2021 Jesmond Capital Ltd. JES.P 19-02-2021 Star Royalties Ltd. STRR 19-02-2021 Gravitas One Capital Corp. GONE.P 22-02-2021 County Capital 2 Ltd. CTWO.P 23-02-2021 Four Arrows Capital Corp. AROW.P 25-02-2021 Zacatecas Silver Corp. ZAC 02-03-2021 Avalon Works Corp. AWB 03-03-2021 SPC Nickel Corp. SPC 08-03-2021 Mednow Inc. MNOW 08-03-2021 AF2 Capital Corp. AF.P 15-03-2021 The Very Good Food Company Inc. VERY 17-03-2021 Mayfair Gold Corp. MFG 22-03-2021 Starlight U.S. Multi-Family (No.2) Core Plus Fund SCPT.A 31-03-2021 Apolo IV Acquisition Corp. AIV.P 01-04-2021 Great Bear Royalties Corp. GBRR 05-04-2021 POCML 6 Inc. POCC.P 06-04-2021 Cannara Biotech Inc. LOVE 08-04-2021 Anacott Acquisition Corporation AAC.P 13-04-2021 Rider 2 Investment Capital Corp. RIDR.P 14-04-2021 New Target Mining Corp. NEW 15-04-2021 Just Kitchen Holdings Corp. JK 15-04-2021 Sierra Madre Gold and Silver Ltd. SM 19-04-2021 Germinate Capital Ltd. GCAP.P 20-04-2021 Nobel29 Resources Corp NBLC 20-04-2021]]><![CDATA[TSX Back in Plus Territory ]]>Wed, 21 Apr 2021 04:30:00 EST, April 21, 2021

16:30 PM EST
TSX Back in Plus Territory

Organigram, Centerra in Focus

Stocks recovered partially Wednesday from the drubbing of the past two days, led by advances in health and resource sectors.

The TSX gained 102.47 points to conclude Wednesday at 19,143.25.

The Canadian dollar rocketed 0.73 cents to 80.02 cents U.S.

Among the chief gainers was Organigram Holdings, moving ahead 22 cents, or 7.5%, to $3.16, while Aurora Cannabis added 54 cents, or 5.6%, to $10.16.

In gold, Centerra Gold improved 39 cents, or 3.3%, to $12.08, while New Gold prospered six cents, or 2.7%, to $2.27.

In other resource stocks, Endeavour Silver gained 37 cents, or 5.5%, to $7.16, while Fortuna Silver Mines brightened 38 cents, or 4%, to $9.94.

Consumer staples weighed the index down, however, with Metro collapsing $1.06, or 1.8%, to $58.25, while Empire Company subtracted 31 cents to $40.27.

In industrials, Boyd Group let go of $5.80, or 2.5%, to $224.20, while Aecon Group ditched 24 cents, or 1.2%, to $19.40.

Communications suffered, too, with Corus Entertainment losing eight cents, or 1.3%, to $5.96, with Shaw Communications dipping 14 cents, to $34.80.

In the economic docket, Statistics Canada says March’s Gross Domestic Product rose 2.2% on a year-over-year basis, up from a 1.1% gain in February. On a seasonally adjusted monthly basis, the CPI rose 0.1% in March.

Also, the Bank of Canada today held its target for the overnight rate at the effective lower bound of 0.25%, with the Bank Rate at 0.5% and the deposit rate at 0.25%


The TSX Venture Exchange sprang back up again 14.15 points, or 1.6%, to 928.91.

All but three of the 12 TSX subgroups were positive by Wednesday’s close, as health-care shot up 3.5%, gold prospered 1.2%, and materials jumped 1%.

The three laggards were consumer staples, down 0.3%, while industrials and communications each gave back 0.1%.


U.S. stocks rose on Wednesday to recover from two straight days of losses as investors piled into shares most sensitive to the economic recovery.

The Dow Jones Industrials restocked 316.01 points to close Wednesday at 34,137.31

The S&P 500 regained 38.48 points to 4,173.42.

The NASDAQ Composite popped 163.95 points to 13,950.22.

Shares of Norwegian Cruise Line Holdings led a pop in reopening plays after Goldman Sachs upgraded the stock. Norwegian jumped more than 10%, while Carnival picked 6.3%, and Royal Caribbean rose 4.4%.

United Airlines rebounded 3% after plunging 8.5% on Tuesday as the carrier reported its fifth consecutive quarterly loss and said that business and international travel is still far from a recovery.

Netflix shares plunged over 7% after the streaming giant reported subscriber additions that fell far short of Wall Street estimates as the demand surge from the pandemic started to fade. The company also said it only expects to add about one million subscribers in the current quarter, well below estimates.

More than 70 S&P 500 companies have reported so far, and they posted a 23% upside to analysts’ earnings expectations on average.

The State Department said it would increase "do-not-travel" advisories to 80% of the world’s countries, adding that the pandemic presents an "unprecedented risk to travelers."

Prices for 10-Year Treasurys gained ground, lowering yields to Tuesday’s 1.56%. Treasury prices and yields move in opposite directions.

Oil prices doffed $1.63 to $61.04 U.S. a barrel.

Gold prices zoomed $16.30 to $1,794.70 U.S. an ounce.

<![CDATA[Stocks in Play: OpSens Inc.]]>Wed, 21 Apr 2021 11:33:09 EST, April 21, 2021

11:33 AM EST - OpSens Inc. : Today announced it has signed an agreement with Cathmedical Cardiovascular S.A. for the integration of its coronary physiology algorithms into the Picasso system, a next generation hemodynamic system. The integrated systems will initially focus on the Spanish cardiology market where the Picasso has a dominant market share. OpSens Inc. (T.OPS) shares were down $0.01 at 1.7.

<![CDATA[Seeking Gold in Volcanos Leads To 10% Rally In Junior Miner]]>Wed, 21 Apr 2021 03:10:26 EST, April 21, 2021

Seeking Gold in Volcanos Leads To 10% Rally In Junior Miner

Baru Gold Corp. (TSX-Venture:BARU) is looking for gold in the volcanic ash of Indonesia.

The company is in the process of acquiring land on Sangihe Island and has a license for production on 42,000 hectares. Baru Gold provided local landowners with an update this morning on the land acquisition process on the project and compensation offered.

COVID-19 and a typhoon have caused recent delays, but Baru Gold expects the land acquisitions to be completed in the coming weeks as there is strong support for the project by island residents and the government.

Baru Gold management plans to operate the Sangihe gold mine in a sustainable manner that is transparent, legal and ethical, and for the benefit of all parties.

Baru Gold Corporation, formerly East Asia Minerals, is positioning itself to become Indonesia’s new gold producer. We are a dynamic junior gold developer with NI43-101 gold resources in Indonesia, one of the top ten gold producer countries in the world.

With sufficient funds and strong retail and institutional shareholder support, Baru Gold is well positioned to take advantage of the increased interest in gold and precious metals with both exploration upsides and operation cashflow in 2021.

The stock was up 10% in late morning trading.

<![CDATA[USD/CAD - Canadian Dollar Consolidating Losses]]>Wed, 21 Apr 2021 08:14:42 EST wheels came off the Canadian dollar rally bus yesterday, and the currency crashed and burned.

USD/CAD soared from $1.2481 to $1.2622 as a wave of risk-aversion sentiment washed over markets. There wasn’t a specific catalyst for the move, but a lack of actionable, top-tier U.S. economic data, and the Federal Reserve’s "cone of silence," ahead of next weeks Federal Open Market Committee meeting, left markets vulnerable.

News of soaring coronavirus deaths in India and reports that the Japanese government planned to declare a state of emergency for Tokyo and Osaka gave rise to fears that the Asia portion of an expected global economic rebound would be delayed. That led to safe-haven demand for Japanese yen and U.S. dollars. Wall Street wobbled on disappointing earnings, then the increase in negative risk sentiment knocked them lower.

The negative sentiment continued in Asia, and the major equity indexes closed with losses led by a 2.0% drop in Japan’s Nikkei 225 index. European traders shrugged off the COVID-19 woes in Asia, and prices were bolstered by better than expected Eurozone corporate earnings. European bourses are trading higher, while Wall Street futures are flat.

Canada is in the market spotlight today. March inflation data, the Bank of Canada monetary policy statement and quarterly Monetary Policy Report (MPR) are on tap.

Headline Consumer Price Index is expected to rise 0.6% m/m compared to 0.5% in February. The BoC monetary policy statement will overshadow the results. Analysts expect the Bank will announce it is tapering Quantitative Easing (QE), and they expect to see upgraded growth forecasts in the MPR report.

EUR/USD rallied from $1.2037 to $1.2079 yesterday, and then the wheels fell off the bus. Prices plunged to $1.2022, then extended the losses to $1.2002 overnight, opening near the bottom in New York.

GBP/USD suffered a similar fate as EUR/USD. Prices peaked at $1.4007 on Tuesday and dropped to $1.3912 just before New York opened. U.K. inflation rose 0.7% y/y in March compared to 0.4% y/y in February, but traders ignored the results.

AUD/USD and NZD/USD suffered from risk aversion sentiment. AUD/USD fell to $0.7701 from $0.7815 yesterday. Australian Retail Sales were better than expected (actual 1.4% m/m vs February -0.8%). NZD/USD tracked AUD/USD price action while dismissing the Q1 CPI report (actual 1.5% q/q vs forecast 1.4%)

The U.S. economic calendar is empty.

Rahim Madhavji is the President of, a Canadian currency exchange that provides better rates than the banks to Canadians]]>
<![CDATA[Citigroup Vaults On Beating Quarterly Projections]]>Thu, 12 Oct 2017 10:07:02 EST per Share came in for the quarter at $1.42, as opposed to $1.32 expected by experts. Revenue was $18.173 billion versus $17.896 billion expected. Fixed income trading: $2.877 billion versus a projected $2.84 billion

Said CEO Michael Corbat, "We had revenue increases in many of the products we have been investing in, tightly managed our expenses, and again saw loan growth in both our consumer and institutional businesses.”

Citi reported a 3% year-over-year increase in global consumer banking revenue. In North America, retail banking revenue rose 12%, excluding mortgages. Citi cited "continued growth in loans and assets under management," as well as higher interest rates.

The bank's international consumer business saw an 8% revenue increase, driven by higher loans and deposit volumes growth.

Citi's end-of-period loans, meanwhile, rose 2% to $653 billion, while deposits increased by 3% to $964 billion.

Shares of Citigroup have risen 26% this year, easily outperforming the broader market. The S&P 500 has gained 14% in 2017.

Citigroup's stock has also outperformed those of other big banks. Shares of JPMorgan Chase and Bank of America are up 11.9% and 16.9%,, respectively.

Folks who follow macroeconomic developments are also aware that Citigroup could benefit from tighter monetary policy in the near future. The U.S. Federal Reserve signaled a December rate hike in the summary of its Sept. 20 meeting.
Shares in C opened Thursday took on 31 cents to $75.25. ]]>
<![CDATA[Enterprise Group’s Hart Oilfield Rentals: Custom, Cost-Effective Infrastructure]]>Thu, 12 Oct 2017 09:51:46 EST

Simply, if you are building a mining or oil business Hart rents customized equipment for project sites, drilling & completions and facilities that require mobile infrastructure.

It makes zero sense to expend valuable capital to purchase generators, offices, WC’s etc. As well, each project is different so flexibility, customization and ease of transport is key.

“Our large competitive advantage is the ability to what we refer to as ‘combo technology,” states Joel Bardwell, Senior Manager at Hart. “Whether on a skid or one of our proprietary portable trailers, we can deliver not only the equipment required, but customize it to be the most cost effective. Customers appreciate the approach and with our ongoing R&D and patent/patent pending profile, both served us well during the downturn and positions us well for the rapidly increasing business, both from previous and new clients.”

Hart currently has 6 locations that are strategically located throughout west central and northern Alberta and northeastern British Columbia. These 6 locations have allowed Hart to establish 6 complimentary “service circles” that slightly overlap and allow Hart to deliver oilfield site set-up services and equipment rentals efficiently to its customers as well as respond quickly to requests for service or repairs to its equipment when required.

Early on, Hart realized that the uniqueness of its approach warranted patent filings for equipment as well as industrial designs. With approximately 25 equally divided between Canada and the US, the practice both cements Hart’s reputation as an innovator as well as protect the Company and Enterprise shareholders from interlopers.

There are always interlopers.

It should also be noted that Hart does not sell the custom equipment. Hart is constantly developing equipment to add to its robust and state of the art rental pool: And all with
safety the primary consideration.

Just as with all the Enterprise Group’s subsidiaries, attention to detail is a given. Reactive and proactive to customer needs is what cuts it out of what is already a small herd. Whether resource, municipal needs, pipelines or any other infrastructure pursuit, that word - infrastructure - should be reflected to a greater or lesser degree in every portfolio. US peers are hitting new highs and others, such as Enterprise’s share price is being wrongly assaulted by a volatile oil price.

The bottom line is that over the years Enterprise has made savvy, money making purchases and sales. TC Backhoe sold in 2016 for approximately C$20 million. The Company was purchased in 2007 for C$12 million and under the Enterprise umbrella generated $150 million. The sale was done during the recent downturn, but had been planned previously and drastically lowered and improved the Company’s financials.

Having successfully steered through a blistering downturn, which seems to have unfairly punish a stock that has a breakup of C$0.85 but is trading at C$0.30, it seems a good addition to a junior portfolio.

Investors will also note that as the Company is traded on the TSX that adds to a list of bonafides to Enterprise that investors would be wise to take stock.

Legal Disclaimer/Disclosure: This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. No information in this Report should be construed as individualized investment advice. A licensed financial advisor should be consulted prior to making any investment decision. We make no guarantee, representation or warranty and accept no responsibility or liability as to its accuracy or completeness. assumes no warranty, liability or guarantee for the current relevance, correctness or completeness of any information provided within this Report and will not be held liable for the consequence of reliance upon any opinion or statement contained herein or any omission. has been compensated ten thousand dollars for its efforts in distributing the TSX:E profile on its web site and distributing it to its database of subscribers. Furthermore, we assume no liability for any direct or indirect loss or damage or, in particular, for lost profit, which you may incur as a result of the use and existence of the information, provided within this Report. ]]>
<![CDATA[WADA Lifts CBD Ban for Professional Athletes and their Doctors]]>Thu, 12 Oct 2017 08:02:09 EST
The World Anti-Doping Agency (WADA) just removed hemp-derived cannabidiol (CBD) from its 2018 List of Prohibited Substances, freeing up athletes in the largest international athletic associations in the world like the IOC and FIFA as well as major sports leagues like UFC, NCAA, NFL, NBA, NHL, MLB, and many more to use CBD-infused products as to treat pain and inflammation based disorders.

As WADA is a global governing body, now athletes around the world can use CBD to treat pain, inflammation and injuries, without the risk of league suspension or a loss of sponsors. Professional athletes around the world can now use Phivida’s CBD infused functional foods and natural health brands, free from WADA restrictions, for the first time in the history of competitive sports.

Cannabinoids have just got mainstream, starting with the major leagues. But it’s investors, and CBD-infused infused functional foods and natural health products brands that stand to benefit the most.

According to Allied Research, the global anti-Inflammatory therapeutics market is projected to top $106 Billion USD by 2020, dominated by OTC drugs like Ibuprofen ($14.2 billion USD by 2022). The US opiate drug as an additional $17.7 billion USD by 2021 dominated by Oxycontin, Percocet and Vicodin. Both the NSAIDs and opiate markets are dominated by pain and inflammation pharmaceutical mogul Bayer (BAYN.DE), with a market capital of over $96 billion.

Cannabidiol is widely studied as a powerful anti-inflammatory and was even part of a US Department of Health patent application for anti-oxidant and neuroprotectant properties.


Timing the market is vital for maximizing investment returns. There is no better example of fortunate timing than WADA’s announcement coinciding with the launch of Phivida Holdings Inc.’s CBD-infused functional foods and natural health products, and the filing of prospectus for an initial public offering and an application to list its class A shares on the Canadian Securities Exchange (CSE).

As a premiere CBD brand, Phivida is perfectly positioned to capture a leadership market share in this emerging global natural health products market. The Phivida IPO offers investors with exposure to three major growth trends within a global health and wellness $1 Trillion USD in 2017.

Bloomberg predicts US cannabinoid products as a $50 billion USD market by 2020. Within the cannabinoids market, Phivida has created its own unique products category – functional CBD edibles.

High Times magazine produces a top ten edibles list and this year six of them were cannabinoid infused beverages. Phivida specializes in the CBD beverages avoiding a saturated confectionary soft drinks market with functional CBD iced teas, CBD protein shakes and CBD vitamin juices.

Health care practitioners, and now sports medicine professionals, and major nutraceutical distributors cite the paradigm shift from chemical based pharmaceuticals to phytonutraceuticals.

Supplements as a whole market is exploding, having gone from a $37 billion US estimate in 2015, to an expectation of $220 billion globally by 2022.

Nutrition Business Journal cites the two fastest growing categories as; meal replacements (14.8%) and sports nutrition (11.6%), two flagship CBD product lines at Phivida – both infused with a high dose of cannabidiol. Phivida’s nanoencapsulation technology loads CBD into a protective, hydrophilic, liposomal membrane that bonds better with cells. The result is a faster acting longer lasting absorption rates, with up to 400% more bioavailability and a timed release for enhanced duration in the bloodstream, and solubility.

Functional foods have surpassed traditional food topping a $100 billion USD back in 2015. The functional food industry is in the process of a massive consolidation as over $10 billion USD of new M&A deals were completed in 2016 alone.

Major food companies are acquiring new organic and functional food brands at a staggering rate, lead by multi-national conglomerates such as Hains Celestial (NASDAQ: HAIN), PepsiCo (NYSE:PEP) and General Mills (NYSE:GIS).

It’s no wonder that major retailers in both the grocery sector, and the nutritional supplements space are champing at the bit to grow their selection of products for consumers.

WADA’s prohibition lift may be the catalyst needed for supplement giant GNC Holdings Inc. (NYSE:GNC) to get its year back on track. Having fallen from over $20 to just over $8 within the year, the ability to introduce new lines of nutritional supplements with pain relieving qualities could be a shot in the arm for GNC.

Whereas major grocery and pharmacy chains, such as Canadian retail giant Loblaw Companies Inc. (TSX:L)(OTC:LBLCF), which owns the well-established Shoppers Drug Mart chain. Unlike GNC, which to-date has been reluctant to carry CBD products in-store, Shoppers Drug Mart has been very open about its willingness to carry CBD and marijuana-related products on its shelves.

It’s still to be determined when and if that same level of acceptance will be seen on the US side of the border. GNC currently doesn’t carry any CBD-infused products, selling only hemp proteins as a remotely close cousin. Nor is CVS Health Corporation (NYSE:CVS), yet.

Online mega-retailer Inc. (NASDAQ:AMZN) is already selling CBD products. On track to hit the very first $1 trillion valuation, Amazon is ahead of the curve on the blossoming CBD sector.

Whole Foods CEO John Mackey stated he would support cannabinoid products sold in Wholefoods “if only the plant was legal to use and the local community approved.”

Not only is CBD-Hemp Oil extract legal under the Farm Bill, but WADA’s new rules has the potential for a massive demand from professional athletes, sports medicine practitioners and alternative health care practitioners and the everyday active health conscious consumer. It looks like John might get his wish.

Plant-based supplements like CBD are no longer limited to the estimated 17,500 licensed alternative health care practitioners, as majority of supplements are now sold through big box FCMD (food, club, mass and drug) retail locations.

Walgreens, CVS and Walmart combined for a total of 27,087 on-site pharmacists at 15,208 stores across the United States. With Amazon’s acquisition of Wholefoods earlier this year, it’s clear that the majors are looking to capitalize on the health-conscious consumer.

Now it’s a matter of CBD’s true market infiltration to take hold, and for producers to begin stocking only the best CBD infused FFNHP formulations.

Primed and ready to supply these retailers with timely product, Phivida boasts an entire line of CBD functional foods and natural health products, doctor formulated for enhanced athletic performance and everyday preventative health for active families.


Totally legal, and boasting a laundry list of health benefits, cannabidiol (CBD) is making waves through the food and beverage industry in the form of several new products.

So it’s no wonder that any new producer of CBD products will want to seek out the expertise of those already familiar with the food and beverage industry.

Assembling an impressive array of talent, Phivida’s management team is built to master not only its formulation, but also its branding and retail distribution.

Among the names on the company’s deck are Directors Bill Ciprick and James Bailey, who each come with decades of branding and distribution experience for industry heavy-hitters, such as Proctor and Gamble Health Care, and Red Bull Canada.

But for the consumer, the most important aspect to consider beyond retail availability is that of the product’s organic, whole-plant blends and formulations.

Phivida infuses full-spectrum CBD Hemp Oil extracts into special blends of functional foods and natural health products (FFNHP). All nanoencapsulated CBD used in Phivida’s products is hemp-derived from licensed hemp farms and federally legal and eligible for sale in any retail channel.

The company’s CBD-infused functional beverages are nanoencapsulated for enhanced bioavailability, and doctor-formulated for targeted outcomes. Phivida boasts quality-, and safety-tested products that are cGMP manufactured to the highest quality assurance standards.

Phivida CBD Vitamin Drinks use certified organic and plant-based ingredients. Phivida’s CBD infusions are also vegan, gluten- and soy-free with no sugar added and contain at least 35% RDA of Vitamin B complex and Vitamin C.

Other key sports performance ingredients include premium electrolyte replacements, glutamine for muscle, bone and joint repair, resveratrol for added anti-oxidants, blended in an all-natural fruit and vegetable puree with no artificial colours or flavours added.

Former President of the BC College of Naturopaths, Dr. Brian Martin, states; “Phivida offers legal, clinical grade, CBD, third-party tested, and safe for practitioners to recommend to athletes and patients.” Marijuana is federally illegal in the United States, but hemp provides a legal option for clinicians. WADA’s new ruling now opens CBD to team physicians, physiotherapists, nutritionists and kinesiologists. “Phivida is a high-quality brand for athletes who need healthier, non-addictive treatments for pain and inflammation,” said Dr. Martin.

WADA’s now-positive stance on CBD represents a great opportunity for Phivida. Competitive athletes in high-impact sports like football, hockey and mixed martial arts are often plagued with a lifetime of debilitating physical injuries and mental health conditions.

Phivida’s CBD infusions give athletes, their trainers, and medical staff a whole-plant nutraceutical alternative to highly addictive opiate pharmaceuticals to treat chronic pain and inflammation from these injuries and afflictions.


Earlier this year, the New York Times published a neuropathology study that found that 99% of former NFL players tested positive for Chronic Traumatic Encephalopathy (CTE). The NFL supports the NFL Players Association’s (NFLPA) study on the use of cannabinoids to treat chronic pain inflammation based disorders, like CTE, according to a Sports Illustrated article published on August 1st, 2017.

The NFLPA was coincided by the launch of the Your Mind Your Body Campaign designed to equip current and former players with the tools needed to achieve a healthy lifestyle, both physically and mentally and encourages an open dialogue on pressing health and safety issues, including CTE, and mental health.

Use of cannabinoid-based alternatives to opiates is not a new issue for the NFL. Many former players have become advocates for CBD as alternatives to narcotics, including former Baltimore Raven Eugene Monroe, Denver Bronco Jake Plummer, Chicago Bear Jim McMahon, and Ricky Williams who publicly stated a belief that “60-70% of all NFL athletes use medicinal marijuana”.

Despite the fact that both the NFLPA and NFL endorse a study of marijuana as a potential pain-management tool, the NFL currently suspends players who test positive for the drug and modified the threshold for a positive test for marijuana (i.e. THC). Finally, WADA’s new adoption of CBD as an approved substance, gives the NFL and its players hope for immediate relief, without controversy.

Phivida’s CBD-infused functional foods and natural health products are formulated with a special blend of nutraceuticals for enhanced athletic performance, and infused with a therapeutic dose of nanoencapsulated cannabidiol from hemp.

"This pain is never going away. My body is damaged," Eugene Monroe, 30, stated in a Washington Post article. "I have to manage it somehow. Managing it with pills was slowly killing me.”

With the lift on the CBD ban, WADA is finally taking sensible action on behalf of the athletes it is tasked to protect.

“Cannabidiol is no longer prohibited,” WADA said, maintaining that THC will remain as a banned substance. WADA cited the reason for the removal of cannabidiol from the banned list was because “it is not a cannabimimetic and does not mimic the effects of THC.”

WADA further clarified: “THC is still a prohibited substance.”

THC or tetrahydrocannabinol is the psychotropic chemical compound in marijuana that contributes to euphoric effects. Many CBD products on the market are marijuana derived and contain THC.

Purity levels in CBD-infused products will give an industry advantage to those producers that can utilize the most CBD, without delivering any THC.

Phivida’s nanoencapsulated CBD-Hemp Oil extracts, edibles and infusions, are federally legal, derived from Farm-Bill-compliant farms, and are now 100% WADA-compliant sources for cannabidiol. As well, they’re coming to a store near you.

Legal Disclaimer/Disclosure: This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. No information in this Report should be construed as individualized investment advice. A licensed financial advisor should be consulted prior to making any investment decision. We make no guarantee, representation or warranty and accept no responsibility or liability as to its accuracy or completeness. assumes no warranty, liability or guarantee for the current relevance, correctness or completeness of any information provided within this Report and will not be held liable for the consequence of reliance upon any opinion or statement contained herein or any omission. has been compensated eight hundred dollars for its efforts in distributing the Phivida article. Furthermore, we assume no liability for any direct or indirect loss or damage or, in particular, for lost profit, which you may incur as a result of the use and existence of the information, provided within this Report.
<![CDATA[Valeant (VRX) Cleans Up its Debt]]>Thu, 12 Oct 2017 07:40:19 EST
Valeant, on October 3, issued a $1-billion debt offering that lower the total upcoming maturities.

Valeant priced its $1-billion principal amount of 5.5% senior notes due in 2025. It will use the proceeds to roll over existing debt. The issuance is not trivial: the lower interest will save the company money while simultaneously pushing out the maturity date.

The low interest rate offered suggests the market has a healthy appetite for Valeant’s debt, so the fear of any bankruptcy is now off the table. Valeant now has around $26 billion in debt and $24 billion net of cash. In June, the company’s net debt was $26.7 billion. The sale of Dendreon raised $811 million, while iNova brought in $923 million. The net effect is that Valeant will have $3.9 billion maturing in 2020.

Assuming Valeant generates $1 billion in free cash flow, the company’s interest on debt in 2020 are covered. It sets the stage for refinancing for the debt due in 2021 and beyond.
<![CDATA[Athersys Hikes on MultiStem Hookup with Japanese Firm ]]>Wed, 11 Oct 2017 12:24:52 EST on the agreement, Athersys and NCLi will engage in technology transfer activities at NCLi’s facility in Japan, and NCLi will begin contract manufacturing support for commercial development of the product in Japan. Athersys’ collaborator, HEALIOS K.K. (Healios), has an exclusive license to develop and market MultiStem in Japan for ischemic stroke, and is currently conducting its registrational clinical study, TREASURE, in Japan.

A news release issued Wednesday claimed therapeutic treatment with MultiStem may extend the stroke treatment window to 36 hours from the current three to four-and-a-half hours with existing standard of care, which would enable many more stroke patients to receive treatment than under the current standard of care and may also meaningfully enhance patient recovery.
Currently, there are nearly 17 million people that suffer a stroke globally and, on average, someone in the United States has a stroke every 40 seconds.
Athersys shares gained 11 cents, or 4.9%, midday Wednesday to $2.34, within a 52-week trading range of $1.02 to $2.63.
<![CDATA[Delta Gains Altitude on Q3 Earnings]]>Wed, 11 Oct 2017 11:12:22 EST number-two U.S. airline reported adjusted earnings per share of $1.57, beating analysts' expectations of $1.53 a share for a quarter that ended with hurricanes that crippled operations.

Earnings per share were about 8% lower over the year-earlier period.

The airline posted quarterly revenue of $11.06 billion, slightly higher than expectations for $11.03 billion in the three months ended in September.

Delta's passenger revenue per available seat mile — a key income metric — rose 1.9%, in line with the airline's updated forecast earlier last month. It said it expects a 2% to 4% increase in passenger unit revenue in the fourth quarter, but warned that higher fuel costs would likely crimp operating margins for the last three months of the year.

Delta posted higher revenue in domestic and Latin American and trans-Atlantic operations, despite powerful storms in the Southern U.S. in August and September.

Delta executives will likely address the impact from deadly storms that hit carriers' hubs late this summer, as well as a bitter trade dispute between two Delta suppliers, Boeing and Canada's Bombardier.

Hurricane Irma, which struck Florida and Delta's hub in Atlanta, forced the airline to cancel more than 2,000 flights.

Delta shares began Wednesday’s trading up 37 cents to $53.07
<![CDATA[BlackRock Rocks Markets on Q3 Figures ]]>Wed, 11 Oct 2017 10:42:55 EST assets under management rose 17% to nearly $6 trillion as net inflows easily beat Wall Street expectations.

Here's how the company's results compare to Wall Street's expectations: EPS came in at $5.92 per share, compared with $5.56 expected. Revenue was $3.233 billion versus $3.096 billion expected.

Total assets under management registered at $5.977 trillion versus experts’ projected $5.94 trillion.
Net inflows were $96 billion versus $71.62 billion expected.
BlackRock also said its iShares exchange-traded funds business saw $52.3 billion in long-term net inflows, led by $33.1 billion in equity inflows. Assets under management for iShares totaled $1.640 trillion, accounting for 27% of BlackRock's total assets.

The company said cash assets rose 6 percent from a year earlier to $425.4 billion.

"One of the greatest problems we still have in the world is how much money is sitting on the sideline," according to CEO Larry Fink. "Even in places like Japan, there's $5 trillion in cash earning negative return. In Germany 72% of savings are in bank accounts. We're seeing some of that unlocked (and), we're seeing people put some of that money to work."

The company's stock has been on fire this year, advancing 21.5%. By comparison, the overall S&P 500 is up about 14% in the period. BlackRock shares have also outperformed the financials sector, which is up 13% in 2017.
BlackRock shares opened Wednesday up $2.80 to $468.29 ]]>
<![CDATA[Emblem Positioned to be Disruptive in the Medical Cannabis Industry]]>Wed, 11 Oct 2017 08:44:45 EST
First, it has become apparent that for the foreseeable future, a few select Canadian marijuana companies will lead the sector growth, particularly over the US.

Second, the virtually unlimited growth in the space will and is being realized through the pharmaceutical developments, particularly in the pain, sleep and anxiety markets. Pain markets alone are $60 billion and will rise over 30% to $83 billion by 2024. Pain and sleep markets are two of the largest component markets.

Key to this growth at companies such as Emblem (TSXV:EMC) is when society embraces marijuana as what could well be the first line of defense and treatment for many afflictions, including the devastating opiate crisis.

“Emblem is focused on developing mainstream medical therapies to deliver consistent, 12-hour relief, with reduced side effects.,” states Gordon Fox, CEO Emblem Corp. “Canada is one of the few jurisdictions in the world –including the USA--with a path to regulatory approval of cannabinoid based medication. ACMPR has mechanisms for approval and these mechanisms are currently being expanded. The Canadian medical community can participate in research and clinical trials and share data and results across provincial boundaries.

With our recently announced exclusive arrangement with CanntabTherapeutics, Emblem is executing to plan.”

The Canntab Deal

Very simply, Canntab has the proprietary sustained release formulation: Emblem is licensed under the Access to Cannabis for Medical Purposes Regulations (the “ACMPR”) to cultivate and sell medical marijuana.

Canada is one of the few jurisdictions in the world with a path to regulatory approval of cannabinoid based medication.

- The current medical cannabis market in Canada is about $400 million. It is searching for better dosage formats. Simple oils have grown to about 35% of the market in less than a year. More appropriate dosage formats are expected to have comparable effects in the market.

- Currently, Cannabis tends to require re-dosing. A titratable, sustained release formulation would have substantial appeal in the chronic neuropathic pain market. Anecdotally, that segment represents a reasonable percentage of the current$400 million medical cannabis market.

- The Canadian non-cannabis chronic pain pharmaceutical market is over $500 million and dominated by opioids and is expected to reach $42.16 billion worldwide by 2021. A cannabinoid based sustained release product has potential to enter that market.

From Emblem’s October 3rd Press Release:

Canntab Therapeutics Limited is a Canadian cannabis oral dosage formulation company based in Markham Ontario, engaged in the research and development of advanced pharmaceutical grade formulations of cannabinoids. Canntab has developed in-house technology to deliver standardized medical cannabis extract from selective strains in a variety of extended/sustained release pharmaceutical dosages for therapeutic use.

The Agreement grants to Emblem the exclusive right in Canada to Canntab’s patents and know-how for the purpose of developing, commercializing, using, selling, and offering the Sustained Release Product for sale under the Emblem brand. The License does not include the right to import or export the Product. The Sustained Release Products will be manufactured by Emblem or by Canntab, after Canntab receives appropriate licensing allowing such manufacture.

As per other Royalty Agreements in the Pharmaceutical Sector terms weren’t disclosed other than ‘double digit” royalty. To be clear this relationship with Canntab is extremely favorable to Emblem.

It cannot be overstated how important a develop this is for patients. Instead of waiting 5-10 years for a therapy to get to patients, cannabis based products take mere months. There is substantial evidence that cannabinoids are effective for the treatment of a number of conditions including (i) chronic pain (ii) nausea, (iii) anxiety and sleep disorders, and (iv) spasticity in patients with Multiple Sclerosis.

The Global Opiate Crisis

While therapies will address particular conditions, anecdotally many patients know and have expressed the efficacy, ease of use and lack of side effects in pain management particularly.

Emblem plans to bring products to deal with neurological pain by fall 2018. Once the 12- hour delivery protocol is established, many afflictions can be addressed via the proper strain and titration.

Investors need to embrace the potential of this market and acquire some exposure. Choose carefully as there are many companies who have and will likely fail or price themselves out of the market.

Emblem’s business plan sets three divisions to be profit centres. From ongoing reasonable to maximum growth:

- Dried flower is the commodity space which provides superior, but generic product

- High quality strains (think aged single malt scotch versus JW Black) for the aficionado

- Top quality strains for ongoing therapeutics’ development.

Margins increase exponentially from dried flower to medical strains. Emblem (TSXV:EMC) is focused on the two markets above dried flower, although will be a major force in all three.

Marijuana Market Maturing Slightly. Invest Carefully, but Invest

The Marijuana space has matured somewhat from mining guys seeing a quick turn in fortunes by announcing some hair-brained participation to get their languishing stock prices up.

Then there the companies who conclude that more marijuana is better and are growing as much as they can.

Finally, there are a few companies, such as Emblem that have a solid growth plan and are not afraid to state their corporate intentions. Many comparisons are made to the UK’s GW Pharma as the direction a developing company should travel.

GW’s Sativex is approved for the treatment of spasticity due to multiple sclerosis in 30 countries outside the United States. The Company has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for glioma, schizophrenia and epilepsy. GW’s ADS on NASDAQ in 2013 came at $8.90. Last trade at this writing was $114.07.

Fun Facts

- Some plant biologists got their early weed (60’s, 70’s) experience by serving time for possession, etc.

- Lots of anecdotal evidence that Big Pharma continues to pay doctors to keep their products at the forefront

The five companies that disclosed what they paid doctors over a six-month period (July to December 2016) were:

- AbbVie (NYSE:ABBV) : $4,104,000

- Novartis (NYSE:NVS) : $3,645,026

- Amgen (NASDAQ:AMGN) : $2,365,000

- Bristol-Myers Squibb (NYSE:BMY) : $1,388,187

- Gilead (NASDAQ: GILD) : $539,761

That alone should give Marijuana companies such as Emblem a place in your speculative portfolio.

Oh, yes. 10 percent of patients suffer from Trypanophobia. That fear keeps 20 percent of that number to never seek medical attention. Look it up…

Perhaps with the inevitable insertion of Marijuana based therapies should reduce or eliminate that number.

And how would Big Pharma ‘payola’ doctors for such a readily available and efficacious therapy? Bueller?

Next couple of decades should be interesting; with less pain, more sleep, relief from chronic disease as well as lives saved.

Legal Disclaimer/Disclosure: This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. No information in this Report should be construed as individualized investment advice. A licensed financial advisor should be consulted prior to making any investment decision. We make no guarantee, representation or warranty and accept no responsibility or liability as to its accuracy or completeness. assumes no warranty, liability or guarantee for the current relevance, correctness or completeness of any information provided within this Report and will not be held liable for the consequence of reliance upon any opinion or statement contained herein or any omission. has been compensated four thousand dollars for its efforts in distributing the TSXV:EMC profile on its web site and distributing it to its database of subscribers. Furthermore, we assume no liability for any direct or indirect loss or damage or, in particular, for lost profit, which you may incur as a result of the use and existence of the information, provided within this Report. ]]>
<![CDATA[AnaptysBio Makes Waves on Trial Data ]]>Tue, 10 Oct 2017 03:25:01 EST CEO Hamza Suria, “we are very encouraged by the efficacy results to date in this Phase 2a study, which exemplify our strategic focus on developing first-in-class anti-inflammatory antibody therapeutics to help patients suffering from debilitating inflammatory diseases.

“We look forward to further advancing the development of ANB020 for the treatment of patients with atopic diseases.”

The Phase 2a study is currently ongoing and EASI scores will be assessed for each patient up to 140 days post-ANB020 treatment. The company plans to report full data from this trial at a medical conference following study completion.

AnaptysBio is a clinical-stage biotechnology company developing what it calls “first-in-class antibody product candidates focused on unmet medical needs in inflammation”.

Its shares neared the close Tuesday up in the stratosphere, leaping in price $31.02, or 88.6%, to $66.02.
<![CDATA[Wal-Mart Hikes on Share Buyback Program]]>Tue, 10 Oct 2017 11:30:29 EST also unveiled a $20-billion share repurchase program to replace its existing plan. The company says the new authorization will be used over a two-year period.

The big-box retailer explained it will continue to focus on remodeling existing stores and incorporating "digital experiences" in place of building new locations.

Ahead of its annual investor day in Bentonville, Arkansas, Wal-Mart said it expects its U.S. e-commerce business to grow sales by roughly 40% in fiscal 2019. Online transactions surged 60% during the second quarter of this year, the retailer declared in August.

The company still expects adjusted earnings per share for the fiscal year 2018 to fall between $4.30 and $4.40.

For fiscal 2019, Wal-Mart said it expects earnings to increase about 5% year over year. Net sales for fiscal 2019 are expected to grow close to 3%, driven by same-store and e-commerce sales growth, the company added.

In fiscal 2019, across the U.S., Walmart will open fewer than 15 Supercenters and fewer than 10 of its Neighborhood Markets.

For fiscal years 2018 and 2019 combined, Wal-Mart is calling for capital expenditures to be about $11 billion, with e-commerce investments going toward enhancing the retailer's supply chain. Wal-Mart's international business will also invest more in fulfillment capabilities.

Shares in Wal-Mart galloped $3.53, or 4.4%, to $84.06